Clinical Oncology
Volume 22, Issue 2 , Pages 140-146, March 2010

Is There a Role for Adjuvant Hysterectomy after Suboptimal Concurrent Chemoradiation in Cervical Carcinoma?

  • N. Walji

      Affiliations

    • The Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
    • Corresponding Author InformationAuthor for correspondence: N. Walji, The Cancer Centre, Queen Elizabeth Hospital, Vincent Drive, Birmingham B15 2TH, UK. Tel: +44-121-697-8319; Fax: +44-121-627-2443.
  • ,
  • A.L. Chue

      Affiliations

    • The Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
  • ,
  • C. Yap

      Affiliations

    • Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, Birmingham, UK
  • ,
  • L.J. Rogers

      Affiliations

    • Pan-Birmingham Gynaecology Cancer Centre, City Hospital, Birmingham, UK
  • ,
  • A. El-Modir

      Affiliations

    • The Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK
  • ,
  • K.K. Chan

      Affiliations

    • Birmingham Women's Hospital, Birmingham, UK
  • ,
  • K. Singh

      Affiliations

    • Pan-Birmingham Gynaecology Cancer Centre, City Hospital, Birmingham, UK
  • ,
  • I.N. Fernando

      Affiliations

    • The Cancer Centre, Queen Elizabeth Hospital, Birmingham, UK

Received 26 June 2009; received in revised form 9 October 2009; accepted 10 November 2009.

Abstract 

Aims

Failure to carry out intracavitary brachytherapy (ICBT) in cervical carcinoma results in suboptimal chemoradiation and increases the risk of recurrence. The aim of this study was to investigate the role of adjuvant hysterectomy after unsuccessful ICBT.

Materials and methods

A retrospective analysis was carried out of all women referred with cervical carcinoma between January 1999 and July 2007 where ICBT insertion was unsuccessful after the initial chemoradiation. The data collected and analysed included histology, stage of disease, causes for unsuccessful ICBT insertion, the response to the initial chemoradiation, subsequent treatment, morbidity, recurrence rates and survival rates. Kaplan–Meier and Log-rank methods were used to analyse recurrence-free and overall survival rates.

Results

ICBT insertion was unsuccessful in 19 of 208 (9%) patients. The causes of failure were: inability to dilate the cervix; uterine perforation; vesicovaginal fistula; patient refusal; other problems, including the presence of pyometrium, patient not fit for general anaesthetic, and narrow vagina; and consultant choice with no obvious reason. Fourteen of 19 patients (74%) received further pelvic external beam radiotherapy (EBRT) alone; five (26%) patients underwent adjuvant hysterectomy. The median follow-up for all patients was 63 months; 60 months for patients treated with adjuvant hysterectomy (range 31–68 months) and 85 months for patients treated with further EBRT. None of the patients treated with adjuvant hysterectomy developed any significant late toxicity. Seven patients (50%) treated with EBRT have relapsed compared with none in the adjuvant hysterectomy arm (P=0.068). Six patients (43%) in the EBRT arm have subsequently died of recurrent disease compared with none in the adjuvant hysterectomy arm (P=0.152).

Conclusions

Adjuvant hysterectomy after unsuccessful ICBT does not seem to increase late toxicity and reduces the risk of pelvic recurrence and may improve survival. The role of adjuvant hysterectomy after suboptimal chemoradiation merits further investigation in clinical trials.

Key words: Brachytherapy, cervical carcinoma, chemoradiotherapy, hysterectomy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0936-6555(09)00376-8

doi:10.1016/j.clon.2009.11.006

Clinical Oncology
Volume 22, Issue 2 , Pages 140-146, March 2010